Parameswaran Hari

27.0k citations
424 papers · 8.0k · 2 hit papers · h-index 43

Impact in

  • Hematology top 0.1%
    • Multiple Myeloma Research and Treatments
    • Hematopoietic Stem Cell Transplantation
  • Oncology top 0.5%
    • CAR-T cell therapy research
    • Peptidase Inhibition and Analysis

Papers in

  • Hematology 265
    • Multiple Myeloma Research and Treatments 202
    • Hematopoietic Stem Cell Transplantation 84
    • Chronic Myeloid Leukemia Treatments 26
  • Oncology 173
    • CAR-T cell therapy research 83
    • Cancer Treatment and Pharmacology 33
Co-authors
Binod Dhakal (89 shared papers)Mehdi Hamadani (81 shared papers)Nirav N. Shah (60 shared papers)Saurabh Chhabra (67 shared papers)Marcelo C. Pasquini (62 shared papers)Anita D’Souza (87 shared papers)Bryon D. Johnson (36 shared papers)William R. Drobyski (26 shared papers)
Journals
Blood (111 papers)Biology of Blood and Marrow Transplantation (72 papers)Journal of Clinical Oncology (31 papers)Bone Marrow Transplantation (19 papers)Leukemia (8 papers)
Partner nations
United StatesGermanyUnited Kingdom

In The Last Decade

Parameswaran Hari

404 papers receiving 7.8k citations

Parameswaran Hari's Hit Papers

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial 2023 · 82 citations
820+2+4Years since publication100200300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2023 The Lancet Haematology
  2. 2020 Nature Medicine

Peers

Parameswaran Hari
Comparison fields: 5 of 120
  • Hematology 4.2k
  • Oncology 3.3k
  • Genetics 777
  • Immunology 1.0k
  • Molecular Biology 3.1k
Replace Seema Singhal with:
Seema Singhal United States
Donna Reece Canada
Ravi Vij United States
Bronno van der Holt Netherlands
Jamie Cavenagh United Kingdom
James R. Berenson United States
William Bensinger United States
Kwee Yong United Kingdom
Michèle Cavo Italy
David B. Miklos United States
Parameswaran Hari relative to Seema Singhal United States Seema Singhal's profile →
Citations per field
00.5×2×4×6.5×
Seema Singhal · 1×
Citations per year

Countries citing papers authored by Parameswaran Hari

Since Specialization
Citations

This map shows the geographic impact of Parameswaran Hari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parameswaran Hari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parameswaran Hari more than expected).

Fields of papers citing papers by Parameswaran Hari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parameswaran Hari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parameswaran Hari. The network helps show where Parameswaran Hari may publish in the future.

Co-authors

The 25 scholars most cited alongside Parameswaran Hari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Parameswaran Hari Line = papers co-authored together Parameswaran Hari links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 424 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nature Medicine ·Nirav N. Shah, Bryon D. Johnson, Dina Schneider, Fenlu Zhu, Anikó Szabó, Carolyn A. Keever-Taylor, Winfried Krueger, Andrew Worden, Michael J. Kadan, Sharon Yim, Ashley M. Cunningham, Mehdi Hamadani, Timothy S. Fenske, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari
Hit paper breakdown →		2020334
2
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Blood ·Shaji Kumar, Ian W. Flinn, Paul G. Richardson, Parameswaran Hari, Natalie S. Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert M. Rifkin, Jeffrey L. Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar
2012319
3
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
The Lancet Oncology ·Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Ai-Min Hui, S. Vincent Rajkumar, Paul G. Richardson
2014204
4
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Clinical Cancer Research ·Dan T. Vogl, Noopur Raje, Sundar Jagannath, Paul G. Richardson, Parameswaran Hari, Robert Z. Orlowski, Jeffrey G. Supko, David Tamang, Min Yang, Simon S. Jones, Catherine Wheeler, Robert J Markelewicz, Sagar Lonial
2017198
5
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Journal of Clinical Oncology ·Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander
2021151
6
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Frontiers in Oncology ·Nirav N. Shah, Theresa Maatman, Parameswaran Hari, Bryon D. Johnson
2019133
7
Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
Biology of Blood and Marrow Transplantation ·Parameswaran Hari, Jeanette Carreras, Mei-Jie Zhang, Robert Peter Gale, Brian J. Bolwell, Christopher Bredeson, Linda J. Burns, Mitchell S. Cairo, César O. Freytes, Steven C. Goldstein, Gregory A. Hale, David J. Inwards, Charles F. LeMaistre, Dipnarine Maharaj, David I. Marks, Harry C. Schouten, Shimon Slavin, Julie M. Vose, Hillard M. Lazarus, Koen van Besien
2008116
8
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction
JAMA Oncology ·Binod Dhakal, Anikó Szabó, Saurabh Chhabra, Mehdi Hamadani, Anita D’Souza, Saad Z. Usmani, Rita Sieracki, Bishal Gyawali, Jeffrey L. Jackson, Fotis Asimakopoulos, Parameswaran Hari
2018116
9
Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell–Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303
Biology of Blood and Marrow Transplantation ·Steven M. Devine, Shelly Carter, Robert J. Soiffer, Marcelo C. Pasquini, Parameswaran Hari, Anthony S. Stein, Hillard M. Lazarus, Charles Linker, Edward A. Stadtmauer, Edwin P. Alyea, Carolyn A. Keever-Taylor, Richard J. O’Reilly
2011106
10
Access to hematopoietic stem cell transplantation
Cancer ·Thomas V. Joshua, J. Douglas Rizzo, Mei‐Jie Zhang, Parameswaran Hari, Seira Kurian, Marcelo C. Pasquini, Navneet S. Majhail, Stephanie J. Lee, Mary M. Horowitz
2010105
11
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Blood ·Simon J. Harrison, Monique C. Minnema, Hans C. Lee, Andrew Spencer, Prashant Kapoor, Deepu Madduri, Jeremy T. Larsen, Sikander Ailawadhi, Jonathan L. Kaufman, Marc S. Raab, Parameswaran Hari, Shinsuke Iida, Ravi Vij, Faith E. Davies, Robin Lesley, Vijay Upreti, Zhao Yang, Anjali Sharma, Alex C. Minella, Suzanne Lentzsch
2020101
12
NF-κB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145
Blood ·Sanja Vodanovic‐Jankovic, Parameswaran Hari, Paulette Jacobs, Richard Komorowski, William R. Drobyski
200593
13
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
Cytotherapy ·Fenlu Zhu, Nirav N. Shah, Huiqing Xu, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Parameswaran Hari, Carolyn A. Keever-Taylor
201790
14
Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation ·William R. Drobyski, Marcelo C. Pasquini, Kathy Kovatovic, Jeanne Palmer, J. Douglas Rizzo, Ayman Saad, Wael Saber, Parameswaran Hari
201188
15
Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study
The Lancet Haematology ·Binod Dhakal, Lisa Baumann Kreuziger, Lisa Rein, Ariel Kleman, Raphael Fraser, Richard H. Aster, Parameswaran Hari, Anand Padmanabhan
201887
16
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
Haematologica ·Arnaud Jaccard, Raymond L. Comenzo, Parameswaran Hari, Philip N. Hawkins, Murielle Roussel, Pierre Morel, M. Macro, Jean‐Luc Pellegrin, Estibaliz Lazaro, Dania Mohty, P. Mercié, Olivier Decaux, JD Gillmore, David Lavergne, Frank Bridoux, Ashutosh Wechalekar, Chris Venner
201485
17
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
Blood ·Binod Dhakal, Sameem Abedin, Timothy S. Fenske, Saurabh Chhabra, Nathan A. Ledeboer, Parameswaran Hari, Mehdi Hamadani
202184
18
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
The Lancet Haematology ·Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander
Hit paper breakdown →		202382
19
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
Clinical Infectious Diseases ·Roy F. Chemaly, Lynn El Haddad, Drew J. Winston, Scott D. Rowley, Kathleen M Mulane, Pranatharthi Chandrasekar, Robin K. Avery, Parameswaran Hari, Karl S. Peggs, Deepali Kumar, Rajneesh Nath, Per Ljungman, Sherif B. Mossad, Sanjeet Dadwal, Ted Blanchard, Dimpy P. Shah, Ying Jiang, Ella Ariza‐Heredia
202079
20
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
Blood ·Vikas Gupta, Parameswaran Hari, Ronald Hoffman
201277

About Parameswaran Hari

Parameswaran Hari is a scholar working on Hematology, Oncology, Molecular Biology, Immunology and Genetics, having authored 424 papers that have together received 8.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (202 papers), Hematopoietic Stem Cell Transplantation (84 papers), CAR-T cell therapy research (83 papers), Protein Degradation and Inhibitors (60 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (41 papers), Chronic Lymphocytic Leukemia Research (37 papers), Cancer Treatment and Pharmacology (33 papers) and Chronic Myeloid Leukemia Treatments (26 papers). The work is most often cited by research in Hematology (4.2k citations), Oncology (3.3k citations), Genetics (777 citations), Immunology (1.0k citations) and Molecular Biology (3.1k citations). Parameswaran Hari has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Binod Dhakal, Mehdi Hamadani, Nirav N. Shah, Saurabh Chhabra, Marcelo C. Pasquini, Anita D’Souza, Bryon D. Johnson, William R. Drobyski, Paul G. Richardson and Timothy S. Fenske. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Bone Marrow Transplantation and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seema SinghalBreakdown of academic impact, for papers by Donna ReeceBreakdown of academic impact, for papers by Ravi VijBreakdown of academic impact, for papers by Bronno van der HoltBreakdown of academic impact, for papers by Jamie CavenaghBreakdown of academic impact, for papers by James R. BerensonBreakdown of academic impact, for papers by William BensingerBreakdown of academic impact, for papers by Kwee YongBreakdown of academic impact, for papers by Michèle CavoBreakdown of academic impact, for papers by David B. Miklos